Glenmark Pharmaceuticals announces launch of Leucovorin Calcium 350 mg injectionGlenmark Pharmaceuticals announces launch of Leucovorin Calcium 350 mg injection

Introduction

Leading pharmaceutical company will launch Leucovorin Calcium for Injection USP, 350 mg/vial Single-Dose Vial, bioequivalent to the reference drug, with distribution starting December 2025 and a $16.8 million market.

Also Read: Zaggle Prepaid shares jump after company announces major partnership with Mastercard Asia Pacific

Share price movement of Glenmark Pharmaceuticals

On December 11, 2025, Glenmark Pharmaceuticals Ltd opened at ₹1,953.95, up 0.16% from its previous close of ₹1,952.90. The stock reached a high of ₹1,967.35 (0.73%) and a low of ₹1,946.25. By 11:13 AM, it traded at ₹1,956.15, a 0.17% increase, with a market cap of ₹55,202.71 crore.

Glenmark to Launch Leucovorin Injection

Glenmark Pharmaceuticals Inc., USA announced the launch of Leucovorin Calcium for Injection USP, 350 mg/vial Single-Dose Vial. The product is bioequivalent and therapeutically equivalent to Hospira’s reference drug.

Distribution of Glenmark’s Leucovorin Calcium for Injection USP, 350 mg/vial Single-Dose Vial will begin in December 2025. The product is approved only for the indications listed on Glenmark’s label.

IQVIA® sales data for the 12 months ending October 2025 shows the Leucovorin Calcium, 350 mg/vial market achieved approximately $16.8 million in annual sales, including brand and therapeutic equivalents.

Stock performance of Glenmark Pharmaceuticals for Period of 1 week, 6 months, and 1 year

Glenmark Pharmaceuticals Ltd delivered a -1.17% return over the past week, it gained 16.8% in the past six months. The stock rose 27.8% over the past year.

Also Read: Kalpataru Projects rises 3% after new project order worth ₹2,003 Cr

Shareholding pattern of Glenmark Pharmaceuticals

Particulars	Sep 2025	Jun 2025	Mar 2025
Promoter	46.70%	46.70%	46.70%
FII	20.70%	20.60%	23.20%
DII	18.70%	17.70%	14.60%
Public	14.00%	15.10%	15.60%

About Glenmark Pharmaceuticals

Glenmark Pharmaceuticals Ltd (NSE: GLENMARK) is a global, research-led pharmaceutical company operating in Branded, Generics, and OTC segments, with focus on respiratory, dermatology, oncology, 11 manufacturing facilities, operations in 80+ countries, and recognized R&D.

Stay Ahead with the Latest Stock Market Updates – Click Here

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.

FAQs